Premarket Clinical Evidence Strength and Recalls of High-Risk Therapeutic Medical Devices.
PMID: 42566203 ·
M, a, r, y, a, m, , M, o, o, g, h, a, l, i, ;, , F, a, a, i, z, a, h, , A, r, s, h, a, d, ;, , V, i, n, a, y, , K, , R, a, t, h, i, ;, , K, u, s, h, a, l, , T, , K, a, d, a, k, i, a, ;, , A, l, e, x, a, n, d, e, r, , O, , E, v, e, r, h, a, r, t, ;, , J, o, s, e, p, h, , S, , R, o, s, s, ;, , S, a, n, k, e, t, , S, , D, h, r, u, v, a
広告
抄録
High-risk medical devices approved through the US Food and Drug Administration (FDA) premarket approval (PMA) pathway may be supported by limited premarket clinical evidence, leaving uncertainties about safety. Whether device, premarket clinical evidence, or regulatory characteristics are associated with subsequent device recalls is unknown. To examine the association between device, premarket clinical evidence, and regulatory characteristics and serious recalls among high-risk therapeutic devic
広告
公式ソース
PubMedで見る →データはPubMed / NCBIから取得しています。全文および最新情報は必ず公式記録をご確認ください。